ARMP | Armata Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: AMEX)

Day's Range	1.9100 - 1.9999
52 Week Range	1.8900 - 4.48
Beta	0.69
Implied Volatility	254.94%
IV Rank	29.15%
Day's Volume	12,087
Average Volume	8,342
Shares Outstanding	36,183,100
Market Cap	70,557,045
Sector	Healthcare
Industry	Biotechnology
IPO Date	1994-05-20

Valuation
Profitability
Growth
Health
P/E Ratio	-1.70
Forward P/E Ratio	N/A
EPS	-1.15
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	66
Country	USA
Website	ARMP

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

ARMP's peers: AKTX, APM, APRE, ARAV, ARDS, ANIX, PHGE, ALPN, BYSI, LCTX, PCSA, PRTG, PYPD, SRZN, TPST, MAIA

*Chart delayed

Analyzing fundamentals for ARMP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see ARMP Fundamentals page.

Watching at ARMP technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ARMP Technicals page.